(57 days)
Not Found
Not Found
No
The device description details a chemical reaction-based diagnostic test and does not mention any computational or algorithmic components indicative of AI/ML.
No.
The device is an in-vitro diagnostic test intended to detect the urease enzyme of Helicobacter pylori for presumptive diagnosis, not to treat a condition or restore a function.
Yes
The "Intended Use / Indications for Use" section explicitly states that "HP-ONE is for in-vitro diagnostic use only. It is intended to detect the urease enzyme of Helicobacter pylori and provide a presumptive diagnosis of H. pylori gastritis." The "Device Description" also confirms it "detects the urease enzyme for the presumptive identification of Helicobacter pylori".
No
The device description clearly outlines a physical test kit involving a tray, reagent, and a biopsy specimen, which are hardware components. The device's function is based on a chemical reaction, not software processing.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Explicit Statement: The "Intended Use / Indications for Use" section clearly states: "HP-ONE is for in-vitro diagnostic use only."
- Device Description: The "Device Description" further reinforces this by stating: "It is intended for in-vitro diagnostic use only."
- Mechanism of Action: The device works by analyzing a biological sample (gastric mucosal biopsy) outside of the body to detect a specific marker (urease enzyme of H. pylori) for diagnostic purposes. This is the core definition of an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
HP-ONE detects the urease enzyme for the presumptive identification of Helicobacter pylori in gastric mucosal biopsies. It is intended for in-vitro diagnostic use only.
HP-ONE is for in-vitro diagnostic use only. It is intended to detect the urease enzyme of Helicobacter pylori and provide a presumptive diagnosis of H. pylori gastritis.
Product codes (comma separated list FDA assigned to the subject device)
83LYR, LYR
Device Description
A gastric mucosal endoscopic biopsy is placed in the HP-ONE tray well and a reagent containing urea, hydrogen peroxide, a pH dye indicator, and an acidic buffer is placed over the biopsy specimen. A bubbling reaction occurs as catalase breaks down the peroxide.
If H. pylori is present, the urease in H. pylori converts the urea to ammonia which raises the pH and changes the color of the reagent, indicating a positive test.
urease (NH2)CO + H2O ------------>NH3 + HCO2 ammonia urea
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
gastric mucosal biopsies
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
In the clinical study of 117 patients with possible peptic ulcer disease, 65 demonstrated positive histological criteria (presence of H. pylori organisms upon staining) for Helicobacter pylori and 52 did not demonstrate the criteria. HP-ONE agreed with the positive histological diagnosis in 60 cases (92.3%) and agreed with the negative diagnosis in all 52 (100%) of the cases. This data provides a relative sensitivity of 92.3% and a relative specificity of 100%.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
HP-One Sensitivity = 92.3% HP-One Specificity = 100%
Positive Predictive Value = 100% Negative Predictive Value = 91.23%
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Not Found
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.3110
Campylobacter fetus serological reagents.(a)
Identification. Campylobacter fetus serological reagents are devices that consist of antisera conjugated with a fluorescent dye used to identifyCampylobacter fetus from clinical specimens or cultured isolates derived from clinical specimens. The identification aids in the diagnosis of diseases caused by this bacterium and provides epidemiological information on these diseases.Campylobacter fetus is a frequent cause of abortion in sheep and cattle and is sometimes responsible for endocarditis (inflammation of certain membranes of the heart) and enteritis (inflammation of the intestines) in humans.(b)
Classification. Class I (general controls).
0
HP-ONE™ 510k SUMMARY
HP-ONE is a trademark of GI Supply division of Chek-Med Systems Inc. Contact Name: Frank Carter
| Address: | 200 Grandview Ave. Camp Hill, PA 17011 |
|---|---|
| Phone #: | 717-761-1170 |
| Fax #: | 717-761-0216 |
PRODUCT NAME: HP-ONE™ 1.
CLASSIFICATION NAME: Campylobacter pylori test - CODE 83LYR 2.
- INTENDED USE: 3.
HP-ONE detects the urease enzyme for the presumptive identification of Helicobacter pylori in gastric mucosal biopsies. It is intended for in-vitro diagnostic use only.
SUMMARY: 3.
Helicobacter pylori has now been shown to be the causative agent in most instances of acute type B gastritis (1). And, it is now known that, in the absence of aspirin, nonsteroidal anti-inflammatory drugs or hyper-secretory states, the bacteria is directly related to peptic ulcer disease such as duodenal and benign gastric ulcers (2). There is epidemiological data linking the presence of the H. pylori with gastric cancer and the lowgrade mucosal associated lymphoid tissue (MALT) lymphoma (3,4). The eradication of H. pylor gastritis by antibiotics has been shown to cure peptic ulcers and prevent recurrence (4,5).
PRINCIPLE: 4.
A gastric mucosal endoscopic biopsy is placed in the HP-ONE tray well and a reagent containing urea, hydrogen peroxide, a pH dye indicator, and an acidic buffer is placed over the biopsy specimen. A bubbling reaction occurs as catalase breaks down the peroxide.
If H. pylori is present, the urease in H. pylori converts the urea to ammonia which raises the pH and changes the color of the reagent, indicating a positive test.
urease (NH2)CO + H2O ------------>NH3 + HCO2 ammonia urea
5. STORAGE/STABILITY:
The HP-ONE reagent is stable and provides accurate results for up to 12 months if refrigerated at 2-8°C. Alternatively, the reagent can be stored at room temperature (18-24°C) but the shelf life will be shortened to 3 months. If stored at room temperature, mark the date of receipt on the label and do not use beyond 3 months. Do not expose to heat or bright light. Do not use the test if the color is not a yellow or yellow-orange color or if the test is past the expiration date. Each HP-ONE reagent bottle contains an expiration date and lot number to permit tracking.
HP-1 SSE rev. 7/01 p.1
1
- SUBSTANTIAL EQUIVALENCE AND DIFFERENCES TO PREDICATE DEVICE: The principle of HP-ONE is substantially equivalent to HP-Fast another product marketed by GI-Supply. They share the same operating principal, but HP-ONE has technical differences from HP-Fast. HP-ONE is a liquid rather than an agar gel and also has a lower pH than HP-Fast. HP-One also contains hydrogen peroxide that acts as a preservative and helps to expedite the urease reaction when H. pylori is present.
SUMMARY OF HP-ONE PERFORMANCE CHARACTERISTICS: 7.
In the clinical study of 117 patients with possible peptic ulcer disease, 65 demonstrated positive histological criteria (presence of H. pylori organisms upon staining) for Helicobacter pylori and 52 did not demonstrate the criteria. HP-ONE agreed with the positive histological diagnosis in 60 cases (92.3%) and agreed with the negative diagnosis in all 52 (100%) of the cases. This data provides a relative sensitivity of 92.3% and a relative specificity of 100%.
| True + | False + | |
|---|---|---|
| HP-One Positives | 60 | 0 |
| HP-One Negatives | False - | |
| 5 | True - | |
| 52 |
HP-One Negatives
Histology Positives = 65 Histology Negatives = 52
HP-One Sensitivity = 92.3% HP-One Specificity = 100%
Positive Predictive Value = 100% Negative Predictive Value = 91.23%
HP-One correctly diagnosed 66.67% of the positives within 5 minutes and 83.3% of the positives by 15 minutes. There were no false positives when diagnosed within the one-hour final reading of the test.
- MEDICAL DEVICE REPORTS / ADVERSE REACTIONS ENCOUNTERED: 8. To date, no MDR's have been filed and no patient adverse reactions have been encountered.
HP-1 SSE rev. 7/01 p.2
2
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of an eagle with its wings spread, depicted in a minimalist, abstract design.
Public Health Service
SEP 2 5 2001
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Mr. Frank Carter President GI Supply, Division of Chek-Med Systems Inc. 200 Grandview Avenue Camp Hill, PA 17011
Re: K012411
Trade/Device Name: HP-ONE Rapid Urea Assay Regulation Number: 21 CFR 866.3110 Regulation Name: Campylobacter Pylori Regulatory Class: I Product Code: LYR Dated: July 27, 2001 Received: July 30, 2001
Dear Mr. Carter:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
3
Page 2 -
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and v additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Butman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Intended Use Certification Section 8.2
510k INDICATION FOR USE STATEMENT
Ko layi ! 510(k) Number (if known): __
Device Name: HP-ONE
Applicant Name: GI Supply division of Chek-Med Systems Inc.
Indication for Use:
HP-ONE is for in-vitro diagnostic use only. It is intended to detect the urease enzyme of Helicobacter pylori and provide a presumptive diagnosis of H. pylori gastritis.
7-26-01
Date:
GI Supply/Chek-Med Signature: c
Frank Carter - CEO
Luedale U. Poole
(Division Sign-Off) Division of Clinical scoratory Devices
510(k) Number K012411
Prescription use